DE60030450D1 - Von MUC-1 abgeleitete Peptide - Google Patents

Von MUC-1 abgeleitete Peptide

Info

Publication number
DE60030450D1
DE60030450D1 DE60030450T DE60030450T DE60030450D1 DE 60030450 D1 DE60030450 D1 DE 60030450D1 DE 60030450 T DE60030450 T DE 60030450T DE 60030450 T DE60030450 T DE 60030450T DE 60030450 D1 DE60030450 D1 DE 60030450D1
Authority
DE
Germany
Prior art keywords
muc
polypeptides
peptides
derived peptides
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030450T
Other languages
English (en)
Other versions
DE60030450T2 (de
Inventor
Joyce Taylor-Papadimitriou
Carl Heukamp
Rienk Offringa
Johanna Melief
Bruce Acres
Mireille Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Cancer Research Horizons Ltd
Original Assignee
Transgene SA
Imperial Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921242.5A external-priority patent/GB9921242D0/en
Application filed by Transgene SA, Imperial Cancer Research Technology Ltd filed Critical Transgene SA
Application granted granted Critical
Publication of DE60030450D1 publication Critical patent/DE60030450D1/de
Publication of DE60030450T2 publication Critical patent/DE60030450T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60030450T 1999-09-08 2000-09-07 Von MUC-1 abgeleitete Peptide Expired - Lifetime DE60030450T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9921242 1999-09-08
GBGB9921242.5A GB9921242D0 (en) 1999-09-08 1999-09-08 Cancer vaccine and diagnosis
EP99402237 1999-09-10
EP99402237 1999-09-10
US18721500P 2000-03-03 2000-03-03
US187215P 2000-03-03
PCT/EP2000/008761 WO2001018035A2 (en) 1999-09-08 2000-09-07 Muc-1 derived peptides

Publications (2)

Publication Number Publication Date
DE60030450D1 true DE60030450D1 (de) 2006-10-12
DE60030450T2 DE60030450T2 (de) 2007-08-30

Family

ID=27240232

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030450T Expired - Lifetime DE60030450T2 (de) 1999-09-08 2000-09-07 Von MUC-1 abgeleitete Peptide

Country Status (11)

Country Link
US (3) US20050142640A1 (de)
EP (1) EP1210430B1 (de)
JP (1) JP2003510094A (de)
AT (1) ATE338121T1 (de)
AU (1) AU778701B2 (de)
CA (1) CA2383737C (de)
DE (1) DE60030450T2 (de)
DK (1) DK1210430T3 (de)
ES (1) ES2270870T3 (de)
PT (1) PT1210430E (de)
WO (1) WO2001018035A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
EP1958642A1 (de) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulierung des Zellwachstums durch MUC1
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
EP1697399B1 (de) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
WO2007015171A2 (en) * 2005-06-28 2007-02-08 Biomira, Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
WO2008011672A1 (en) * 2006-07-25 2008-01-31 4G Vaccines Pty Ltd A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
EP2089423B1 (de) 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigenspezifische multi-epitop-impfstoffe
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
CA2716622A1 (en) 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides and methods of making and using them
NZ592537A (en) 2008-10-17 2012-07-27 Dana Farber Cancer Inst Inc Muc-1 cytoplasmic domain peptides as inhibitors of cancer
EP2435062A4 (de) * 2009-05-27 2013-01-02 Dana Farber Cancer Inst Inc Inhibition der entzündung mithilfe von muc1-antagonisten
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
EP2374470A1 (de) 2010-04-08 2011-10-12 Beta Innov Therapeutische Anwendung von Protein Beta-2-M
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
AU2012222188A1 (en) 2011-02-24 2013-08-15 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
MX352892B (es) * 2011-08-17 2017-12-13 Globeimmune Inc Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
WO2013103658A1 (en) * 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
WO2016143814A1 (ja) 2015-03-09 2016-09-15 日本電気株式会社 Ｍｕｃ１由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
EP3903811A1 (de) * 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Pharmazeutische zusammensetzung und verfahren zur induzierung einer immunantwort

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
EP0643726B1 (de) * 1992-05-26 1999-08-18 Rijksuniversiteit te Leiden Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
AU753540B2 (en) * 1998-03-05 2002-10-24 Agouron Pharmaceuticals, Inc. Non-peptide GnRH agents
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies

Also Published As

Publication number Publication date
US20050142640A1 (en) 2005-06-30
ATE338121T1 (de) 2006-09-15
US20100255501A1 (en) 2010-10-07
PT1210430E (pt) 2006-12-29
WO2001018035A3 (en) 2001-11-08
JP2003510094A (ja) 2003-03-18
AU7651500A (en) 2001-04-10
DE60030450T2 (de) 2007-08-30
US7892828B2 (en) 2011-02-22
AU778701B2 (en) 2004-12-16
WO2001018035A2 (en) 2001-03-15
EP1210430B1 (de) 2006-08-30
US20080227082A1 (en) 2008-09-18
CA2383737A1 (en) 2001-03-15
WO2001018035A9 (en) 2002-09-06
ES2270870T3 (es) 2007-04-16
CA2383737C (en) 2011-01-18
DK1210430T3 (da) 2006-11-20
EP1210430A2 (de) 2002-06-05

Similar Documents

Publication Publication Date Title
ATE338121T1 (de) Von muc-1 abgeleitete peptide
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
ATE368053T1 (de) Antimikrobielle peptide
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE69320967T2 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
DE68927379D1 (de) Plättchen blockierende peptide
GB9219936D0 (en) Vaccines
ATE256185T1 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ATE362939T1 (de) Dimere von thrombinpeptidderivaten
ATE225806T1 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
ATE412745T1 (de) Antiangiogene peptide vom n-terminus von endostatin
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
DE69940954D1 (de) Von mage-10 oder mage-8 abgeleitete hla-a2.1-bindende oligopeptide
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
NO993684L (no) Peptider som omfatter et T-celle-epitop spesifikt til kollagen-II
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
ATE260934T1 (de) Therapeutische peptide aus untersequenzen von bpi
AU2003260546A8 (en) Device for the presentation of peptides or proteins, method for the preparation and use thereof
ATE305478T1 (de) Topoisomerase-ii inhibitoren
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition